Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis

Xie, Feng; Zang, Jiajie; Guo, Xiaojing; Xu, Feng; Shen, Ruinan; Long, Yan; Yang, Jiamei; He, Jia

doi:10.1007/s00432-011-1117-7

Cited by 18 publications

(13 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…showed a significantly longer time to progression with TARE than with TACE. A meta‐analysis of retrospective studies from Xie et al . demonstrated a survival benefit of TARE over TACE [HR: 0.73 (95% CI: 0.60–0.88); P = 0.0009].…”

Section: Resultsmentioning

confidence: 99%

Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations

Boily

Villeneuve

Lacoursière

et al. 2015

HPB

View full text Add to dashboard Cite

Considering the evidence available to date, the CEPO recommends the following: (i) transarterial chemoembolization therapy (TACE) be considered a standard of practice for the palliative treatment of HCC in eligible patients; (ii) drug-eluting beads (DEB)-TACE be considered an alternative and equivalent treatment to conventional TACE in terms of oncological efficacy (overall survival) and incidence of severe toxicities; (iii) the decision to treat with TACE or DEB-TACE be discussed in tumour boards; (iv) bland embolization (TAE) not be considered for the treatment of HCC; (v) radioembolization (TARE) not be considered outside of a clinical trial setting; and (vi) sorafenib combined with TACE not be considered outside of a clinical trial setting.

show abstract

Section: Resultsmentioning

confidence: 99%

Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations

Boily

Villeneuve

Lacoursière

et al. 2015

HPB

View full text Add to dashboard Cite

show abstract

“…One meta-analysis compared the outcomes of TACE versus microsphere embolization [123]. Microsphere embolization was superior to TACE in terms of OS, TTP, and tumor response [123].…”

Section: Tacementioning

confidence: 99%

“…Microsphere embolization was superior to TACE in terms of OS, TTP, and tumor response [123]. In the subgroup analyses, the benefit was statistically significant in patients undergoing 32 P glass microspheres, but not in those undergoing 90 Y microspheres.…”

Section: Tacementioning

confidence: 99%

Management of hepatocellular carcinoma: an overview of major findings from meta-analyses

Zhao

et al. 2016

Oncotarget

View full text Add to dashboard Cite

This paper aims to systematically review the major findings from meta-analyses comparing different treatment options for hepatocellular carcinoma (HCC). A total of 153 relevant papers were searched via the PubMed, EMBASE, and Cochrane library databases. They were classified according to the mainstay treatment modalities (i.e., liver transplantation, surgical resection, radiofrequency ablation, transarterial embolization or chemoembolization, sorafenib, and others). The primary outcome data, such as overall survival, diseases-free survival or recurrence-free survival, progression-free survival, and safety, were summarized. The recommendations and uncertainties regarding the treatment of HCC were also proposed.

show abstract

“…in unresectable HCC showed that radioembolisation was significantly better for OS, 1 year survival and TTP compared with TACE. There was a tendency toward a higher response rate in radioembolisation compared to TACE …”

Section: Comparison Of Transcatheter Therapiesmentioning

confidence: 99%

Transarterial chemoembolisation and radioembolisation for the treatment of primary liver cancer and secondary liver cancer: A review of the literature

et al. 2014

View full text Add to dashboard Cite

SummaryLiver-directed therapies are continuing to evolve in the field of interventional oncology and are gaining increasing use in the treatment of unresectable primary and secondary liver cancers. In this article, we review two liverdirected therapies that are currently used for the palliative treatment of primary and secondary hepatic tumours: transcatheter arterial chemoembolisation (TACE), including a new type of TACE with drug-eluting beads (DEB-TACE), and radioembolisation. The concept of these transcatheter intraarterial therapies is to selectively deliver high doses of anticancer treatment to the tumour. While TACE delivers one or more chemotherapeutic drugs into the hepatic arteries supplying the tumour, radioembolisation uses non-embolic microspheres incorporating the radioactive isotope 90 Y. In this article, we discuss some technical aspects, patient selection, current clinical evidence, and future directions of TACE, TACE with drug-eluting beads (DEB-TACE) and radioembolisation for primary and secondary liver cancer.

show abstract

Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis

Abstract: These data demonstrated that microsphere embolization treatment of patients with surgically unresectable HCC provided much better survival and treatment response than that of TACE.

Cited by 18 publications

References 30 publications

Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations

Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations

Management of hepatocellular carcinoma: an overview of major findings from meta-analyses

Transarterial chemoembolisation and radioembolisation for the treatment of primary liver cancer and secondary liver cancer: A review of the literature

Contact Info

Product

Resources

About